Eli Lilly has announced a $140-million expansion of its Indianapolis insulin manufacturing facility.
The new facility will manufacture insulin cartridges to meet the growing diabetes demand in the U.S. Company officials say it is one of the most significant investments in its U.S.-based manufacturing operations in the past 10 years and will be a first-of-its-kind facility for Lilly in the U.S.
Eli Lilly president of global manufacturing Maria Crowe says Lilly decided to add insulin-cartridge manufacturing to its Indianapolis plant, rather than expand existing operations in Europe. The facility will employ 100 full-time workers once it is fully operational. Construction should be complete in March 2014.